0RK Stock Overview An artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. More details
Rewards Risk Analysis See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
Exscientia plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Exscientia Historical stock prices Current Share Price US$4.50 52 Week High US$7.70 52 Week Low US$3.66 Beta 0.84 1 Month Change 1.35% 3 Month Change -14.29% 1 Year Change -21.05% 3 Year Change -73.84% 5 Year Change n/a Change since IPO -77.91%
Recent News & Updates
Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI). Nov 22 Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI).
Third quarter 2024 earnings released: UK£0.40 loss per share (vs UK£0.25 loss in 3Q 2023) Nov 10
Second quarter 2024 earnings released: US$0.36 loss per share (vs US$0.37 loss in 2Q 2023) Aug 16 Exscientia plc Reports Impairment for the Second Quarter Ended June 30, 2024 Aug 15
Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for approximately $640 million. Aug 09
See more updates
Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI). Nov 22 Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI).
Third quarter 2024 earnings released: UK£0.40 loss per share (vs UK£0.25 loss in 3Q 2023) Nov 10
Second quarter 2024 earnings released: US$0.36 loss per share (vs US$0.37 loss in 2Q 2023) Aug 16 Exscientia plc Reports Impairment for the Second Quarter Ended June 30, 2024 Aug 15
Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for approximately $640 million. Aug 09
Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for Aug 08
New major risk - Revenue and earnings growth Jul 09
The Schall Law Firm Announces Class Action Lawsuit Against Exscientia plc Jun 25
Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology Jun 08
First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.38 loss in 1Q 2023) May 22
Exscientia plc to Report Q1, 2024 Results on May 21, 2024 May 16 Holzer & Holzer, LLC Files Class Action Lawsuit on Behalf of Exscientia P.L.C. Investors Apr 30
Exscientia plc, Annual General Meeting, May 15, 2024 Apr 23
New minor risk - Shareholder dilution Mar 24
Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million. Mar 23 Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million. Mar 22
Full year 2023 earnings released: UK£1.18 loss per share (vs UK£0.97 loss in FY 2022) Mar 21
Exscientia plc to Report Fiscal Year 2023 Results on Mar 21, 2024 Mar 15
New minor risk - Shareholder dilution Nov 13
Third quarter 2023 earnings released: UK£0.25 loss per share (vs UK£0.29 loss in 3Q 2022) Nov 10
Exscientia plc to Report Q3, 2023 Results on Nov 09, 2023 Nov 03
Parker Moss to Join Exscientia as EVP, Corporate Development Oct 18
Exscientia plc to Present New Preclinical Data for AI- Designed LSD1 and MALT1 Inhibitors at ESMO 2023 Oct 17
New minor risk - Shareholder dilution Aug 14
Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 2Q 2022) Aug 10
Exscientia plc to Report Q2, 2023 Results on Aug 10, 2023 Aug 04
Exscientia plc Initiates Prospective Observational Study in Ovarian Cancer Jul 21
Exscientia plc Announces First Patient Enrolled in Phase 1/2 ELUCIDATE Trial Assessing GTAEXS617 in Advanced Solid Tumours Jul 11
First quarter 2023 earnings released: US$0.38 loss per share (vs US$0.17 loss in 1Q 2022) May 25
Exscientia plc Highlights "The Future of AI-Enabled Drug Discovery" at SLAS Europe May 23
Exscientia plc to Report Q1, 2023 Results on May 24, 2023 May 19
Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors May 04
Full year 2022 earnings released: UK£0.97 loss per share (vs UK£0.99 loss in FY 2021) Mar 24
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318 Feb 03
Exscientia plc Highlights New Data to Identify Patients That Are More Likely to Respond to Its A2a Receptor Antagonist, Exs-21546 Dec 07
Exscientia plc Receives First clinical trial application Approval to Initiate IGNITE-AI, Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours Nov 29
Exscientia plc to Report Q3, 2022 Results on Nov 15, 2022 Nov 09
Blood Cancer Discovery Publication Further Validates Exscientia's Ai Precision Medicine Platform for Improving Patient Outcomes Sep 21
Exscientia plc Welcomes Caroline Rowland as Chief People Officer Sep 09
Second quarter 2022 earnings released: UK£0.23 loss per share (vs UK£0.71 loss in 2Q 2021) Aug 18
Exscientia plc to Report Q2, 2022 Results on Aug 17, 2022 Aug 11
Exscientia plc Reports Data from EXS-21546 Phase 1A Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers Jun 15
Exscientia plc to Report Q1, 2022 Results on May 25, 2022 May 19
Exscientia plc, Annual General Meeting, May 18, 2022 Apr 23
Exscientia plc Appoints Michael Krams as Chief Quantitative Medicine Officer Apr 06
No independent directors Feb 14
Third quarter 2021 earnings released: UK£0.059 loss per share Nov 20 Shareholder Returns 0RK DE Biotechs DE Market 7D 0% 1.2% 2.3% 1Y -21.1% -5.6% 16.7%
See full shareholder returns
Return vs Market: 0RK underperformed the German Market which returned 7.4% over the past year.
Price Volatility Is 0RK's price volatile compared to industry and market? 0RK volatility 0RK Average Weekly Movement n/a Biotechs Industry Average Movement 5.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: 0RK's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 0RK's volatility change over the past year.
About the Company Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company’s lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies.
Show more Exscientia plc Fundamentals Summary How do Exscientia's earnings and revenue compare to its market cap? 0RK fundamental statistics Market cap €608.29m Earnings (TTM ) -€180.84m Revenue (TTM ) €20.51m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0RK income statement (TTM ) Revenue UK£17.07m Cost of Revenue UK£28.63m Gross Profit -UK£11.56m Other Expenses UK£138.95m Earnings -UK£150.51m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.15 Gross Margin -67.74% Net Profit Margin -881.79% Debt/Equity Ratio 0.1%
How did 0RK perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/11/22 07:58 End of Day Share Price 2024/11/15 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Exscientia plc is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Alec Stranahan BofA Global Research Chris Shibutani Goldman Sachs Brendan Smith TD Cowen
